Tycel Jovelle Phillips, MD, University of Michigan

Articles

Dr. Phillips on the Future of CAR T-Cell Therapy in MCL

August 2nd 2021

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.

ADCs for Relapsed/Refractory DLBCL: Next Steps

July 20th 2021

Tycel Jovelle Phillips, MD, reviews current therapy options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and how he selects among these options and highlights some potential new therapies.

Relapsed/Refractory DLBCL: Sequencing Therapy

July 20th 2021

Tycel Jovelle Phillips, MD, of the University of Michigan, comments on his preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and shares his expectations for sequencing with newer, novel approaches emerging in the field.

Safety of Loncastuximab Tesirine for Relapsed/Refractory DLBCL

July 20th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with loncastuximab tesirine based on safety data from LOTIS-2 and variables that may impact patient candidacy.

Loncastuximab Tesirine for Relapsed/Refractory DLBCL

July 13th 2021

Potential implications for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with loncastuximab tesirine, an antibody-drug conjugate, based on early results demonstrated by the LOTIS-2 study.

Treatment Advances in Relapsed/Refractory DLBCL

July 13th 2021

A historical overview of treatment advances for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and the rationale for treating appropriate patients with an approved antibody-drug conjugate therapy.

Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL

May 7th 2021

Tycel J. Phillips, MD, presents slides from the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 of results from the phase 3 CHRONOS-3 study of copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Next Steps in Mantle Cell Lymphoma

March 2nd 2021

MRD Assessment in Mantle Cell Lymphoma

March 2nd 2021

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

March 2nd 2021

MCL: Emerging BTKi-Combination Approaches

February 23rd 2021

Emerging BTK Inhibitors in Mantle Cell Lymphoma

February 23rd 2021

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

February 16th 2021

Venetoclax in Mantle Cell Lymphoma

February 16th 2021

BTK Inhibitors for Relapsed MCL: Important Considerations

February 9th 2021

Selecting a BTKi for Relapsed MCL Treatment

February 9th 2021

Acalabrutinib and Zanubrutinib for Relapsed MCL

February 2nd 2021

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

February 2nd 2021

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

January 26th 2021

Go-To Treatment Regimens in Mantle Cell Lymphoma

January 26th 2021